Redcare Pharmacy in the news

Redcare Pharmacy's shares rose sharply due to an 82.1% revenue increase in its German prescription business, reversing prior declines.

Redcare Pharmacy's shares have doubled in three years driven by strong revenue growth despite ongoing losses and recent share price volatility.

Redcare Pharmacy's shares rise on strong Q3 results and optimistic analyst forecasts driven by digital healthcare trends.

Redcare Pharmacy's stock shows potential with recent gains and optimistic analyst targets despite an ongoing downtrend.

Redcare Pharmacy's Q3 2025 sales surged 25%, driven by digital healthcare growth and regulatory support, despite some leadership and regulatory risks.

Barclays sees strong growth potential for Redcare Pharmacy due to Germany's mandatory e-prescription rollout, highlighting its attractive valuation and financial stability compared to competitors.

Redcare Pharmacy reported a 25.2% sales increase in Q3 2025, driven by strong Rx growth in Germany and confirmed its full-year guidance with over 13 million active customers.

Redcare Pharmacy's stock rebounded strongly after a 25% revenue surge in Q3 2025, despite a CFO change, signaling a potential turnaround.

Redcare Pharmacy reported a 25% revenue increase in Q3 2025, driven by strong Rx growth in Germany and improved customer metrics, confirming its full-year forecast.

Redcare Pharmacies saw a strong rebound in Q3 German prescription sales, driving a 7% stock rise and confirming full-year 2025 sales targets.

Redcare Pharmacy's Q3 sales surged 25%, boosting its share price amid optimism about regulatory changes and digital prescription growth, though valuation risks remain.

Barclays highlights Redcare Pharmacy as Germany’s leading online medicine company, expecting strong future profits amid growing digital prescriptions.

Redcare Pharmacy's CFO departure ahead of Q3 results spooked investors despite strong financials, causing a significant stock drop amid ongoing growth concerns.

Redcare Pharmacy's shares fell 4% after CFO Jasper Eenhorst announced his departure, amid a 43.6% year-to-date stock decline.

Redcare Pharmacy's CFO resignation amid weak prescription growth led to a sharp stock decline and investor confidence challenges.

Redcare Pharmacy's Q3 sales rose 25% with solid margins, confirming its full-year outlook and boosting shares.

Redcare Pharmacy's CFO Jasper Eenhorst is departing during a crucial growth period, with the CEO temporarily handling finances until a replacement is found.

Redcare Pharmacy's sales recovery and confirmed 2025 targets have led analysts to maintain Buy ratings with optimistic price targets.

Retail investors own 40% of Redcare Pharmacy, with insiders and institutions holding significant stakes, while insiders have recently sold shares.

Jasper Eenhorst is stepping down from Redcare Pharmacy NV's board but will stay until year-end to assist with the transition.